Release Date: November 01, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: How should we think about system placements in Q4, and are there any trends heading into next year? A: Sean Wirtjes, CFO, mentioned that the guidance remains prudent due to market headwinds, such as elongated purchasing cycles and scrutiny in the purchasing process. However, there is room for upside if execution in Q4 exceeds expectations. Robert Spignesi, CEO, added that high ROI projects are being prioritized and funded, which underpins confidence for the balance of the year and into 2025.
Q: What are your expectations for accounts focused on new modalities like biologics and cell and gene therapies? A: Robert Spignesi, CEO, stated that the bulk of their business is in biologics and cell and gene therapies, with strong uptake and a positive outlook. The funnel includes large and mid-size biopharmaceutical companies and CDMOs, with sterility reinforcing funnel growth and access to new areas like sterile injectables.
Q: Can sterility be an incremental positive at the revenue line for 2025? A: Sean Wirtjes, CFO, noted that while it's early days, the value proposition of sterility is resonating well with customers, leading to high interest and positive feedback. The company is focused on translating this interest into business and revenue for 2025, with current leading indicators and funnel build meeting expectations.
Q: Have you crossed the threshold to achieve positive gross margins for products on a quarterly basis? A: Sean Wirtjes, CFO, indicated that while they are on the right trajectory, achieving positive gross margins consistently will depend on product mix and volume. There is a chance to reach positive margins in Q4, with further improvements expected as volumes increase and cost efficiencies are realized.
Q: What is driving the trends in consumables usage among higher-end users like biologics and cell and gene therapies? A: Robert Spignesi, CEO, explained that these categories tend to be higher volume, yielding significant consumable usage. The funnel is largely driven by global pharma companies, with many segments expected to be high yielding, potentially accretive to current consumable usage levels.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。